MDGL—(-8%)—reports 1Q24 results: https://finance.yahoo.com/news/madrigal-pharmaceuticals-reports-first-quarter-110000708.html No revenue was booked in 1Q24 because the Rezdiffra launch occurred in April. MDGL had $1.1B of cash at 3/31/24 thanks to the public offering immediately following FDA approval of Rezdiffra (#msg-174068028).